{
    "ticker": "XBAP",
    "name": "Xenon Biopharma, Inc.",
    "description": "Xenon Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with rare neurological disorders and other unmet medical needs. Founded in 1996, Xenon aims to identify and advance novel therapeutics that target specific genetic mutations and pathways involved in neurological diseases. The company leverages its proprietary technology platforms to discover and develop drug candidates, including XEN1101, a leading candidate for the treatment of epilepsy and other neurological indications. Xenon is distinguished by its commitment to precision medicine, utilizing genetic insights to inform its research and clinical development strategies. The company collaborates with academic institutions and industry partners to enhance its therapeutic pipeline and has a robust portfolio of preclinical and clinical-stage assets. With a mission to improve the lives of patients suffering from debilitating neurological conditions, Xenon is at the forefront of innovation in the biopharmaceutical space.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, British Columbia, Canada",
    "founded": "1996",
    "website": "https://www.xenon-pharma.com",
    "ceo": "Simon Pimstone",
    "social_media": {
        "twitter": "https://twitter.com/XenonPharma",
        "linkedin": "https://www.linkedin.com/company/xenon-pharmaceuticals/"
    },
    "investor_relations": "https://investors.xenon-pharma.com",
    "key_executives": [
        {
            "name": "Simon Pimstone",
            "position": "CEO"
        },
        {
            "name": "Gordon McCauley",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "XEN1101",
                "XEN496"
            ]
        },
        {
            "category": "Research Programs",
            "products": [
                "Rare Neurological Disorders"
            ]
        }
    ],
    "seo": {
        "meta_title": "Xenon Biopharma, Inc. | Innovative Therapies for Neurological Disorders",
        "meta_description": "Discover Xenon Biopharma, Inc., a leader in developing precision medicine for rare neurological disorders. Explore our innovative therapies and commitment to patient care.",
        "keywords": [
            "Xenon Biopharma",
            "Neurological Disorders",
            "Precision Medicine",
            "Epilepsy Treatment",
            "Biopharmaceuticals",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does Xenon Biopharma focus on?",
            "answer": "Xenon Biopharma focuses on developing innovative therapies for rare neurological disorders and other unmet medical needs."
        },
        {
            "question": "Who is the CEO of Xenon Biopharma?",
            "answer": "The CEO of Xenon Biopharma is Simon Pimstone."
        },
        {
            "question": "Where is Xenon Biopharma headquartered?",
            "answer": "Xenon Biopharma is headquartered in Vancouver, British Columbia, Canada."
        },
        {
            "question": "What are Xenon's main products?",
            "answer": "Xenon's main products include XEN1101 and XEN496, both focused on treating neurological disorders."
        },
        {
            "question": "When was Xenon Biopharma founded?",
            "answer": "Xenon Biopharma was founded in 1996."
        }
    ],
    "competitors": [
        "VRTX",
        "AVTX",
        "ALNY",
        "PTCT"
    ],
    "related_stocks": [
        "BIIB",
        "REGN",
        "AMGN",
        "GILD"
    ]
}